

2023年 9月 14日

各位

「Newsweek International」掲載のお知らせ

当社の子会社であるあすか製薬株式会社（東京都港区）の代表取締役社長 山口惣大が、通信社 The Worldfolio PTE. LTD.の取材を受け、米国週刊誌「Newsweek International」に当社の紹介記事が掲載されましたのでお知らせいたします。（記事内容は添付資料をご覧ください。）

Newsweek は、世界に約 4,600 万人の読者を持つ米国の週刊誌で、世界の文化・政治・経済・社会情勢等、あらゆる分野の情報を世界に発信、展開しています。今回、特集企画「Japan leads the way in the healthcare innovation（世界の医療をリードする日本）」に、日本企業の一社として当社を紹介したいとオファーがあり、インタビューが実現しました。

なお、インタビューの全文は、ニュースサイト「The WORLDFOLIO」に掲載されていますので、あわせてお知らせいたします。

「The WORLDFOLIO」ウェブサイト（英文）

<https://www.theworldfolio.com/interviews/aska-we-create-new-value-as-leading-womens-healthcare-company/5872/>

※記事の掲載は The Worldfolio PTE. LTD.の許可を得ています。

The Worldfolio PTE. LTD.：

20 年以上にわたって世界中の読者に高品質のコンテンツを提供してきたメディアエージェンシーです。現在は、シンガポールを拠点に、製造、不動産、建設、ヘルスケア、デジタルトランスフォーメーションなど、幅広いトピックや最新ニュースを提供しています。

以上

<お問い合わせ先>

あすか製薬ホールディングス株式会社 グループ経営企画部 TEL：03-5484-8366

China's Plan to Rule World's Smart Devices

INTERNATIONAL Newsweek®

Forget Keto, Intermittent Fasting and Ozempic.

The facts about what works—and what doesn't—are still elusive



The Search for the Perfect Diet

08-15-09-2023

ISSN 2052-1081



3 6 >

9 772052 108027

ALBANIA €6.25	CZECH REP CZK180	HOLLAND €7.00	LEBANON LL10,000	NORWAY NKR119	SERBIA RSD1035	SWITZERLAND CHF10.60
AUSTRALIA \$11.00	DENMARK DKR57	HONG KONG HK\$80	LITHUANIA €8.99	OMAN OR 3.250	S LEONE SLL30,000	UAE AED42
AUSTRIA €10.00	EGYPT E£ 65.00	HUNGARY FT1,800	LUXEMBOURG €7.90	POLAND PLN29.99	SINGAPORE \$11.95	UK £5.99
BAHRAIN BD3.5	FINLAND €7.50	IRELAND €7.00	MALTA €7.00	PORTUGAL €7.00	SLOVAKIA €6.50	US \$10.99
BELGIUM €7.00	FRANCE €7.50	ISRAEL NIS35	MONTENEGRO €8.30	QATAR QR65	SLOVENIA €8.50	ZIMBABWE ZWD4.00
CHINA RMB80	GERMANY €7.50	ITALY €7.00	MOROCCO MDH70	MALAYSIA RM27.90	SOUTH AFRICA R55.00	
CROATIA HRK70	GIBRALTAR €6.05	KUWAIT KD3.00	NEW ZEALAND \$14.00	ROMANIA LEI 42.00	SPAIN €7.00	
CYPRUS €7.00	GREECE €7.50	LATVIA €6.50	NIGERIA \$3.40C	SAUDI ARABIA SR35.00	SWEDEN SKR119	

ASKA Pharmaceutical looking to be the number one total healthcare company

With drugs for internal medicine, obstetrics and gynecology, and urology, ASKA is making sure that all of its patients' health needs are met.



"We create new value as a leading women's healthcare company."

Sohta Yamaguchi,
President,
ASKA Pharmaceutical Co., Ltd.

First established in 1920, ASKA Pharmaceutical has grown to become the leading company in female healthcare in Japan, and currently occupies the number one sales position domestically in the fields of obstetrics and gynecology.


That status owes much to the group's ability to adapt, and as recently as 2021 the firm changed its management style to a holdings structure, enabling it to provide a holistic service from prevention, examination and diagnosis to treatment and post-treatment. "ASKA Pharmaceutical Holdings Co., Ltd. has several group companies," company president Sohta Yamaguchi explains, "and one of them focuses on pharma-



Head office in Tokyo

ceutical drugs, while another focuses on testing and equipment for early diagnosis and prevention. With this comprehensive approach, we can increase our business opportunities."

One of the group's core businesses is the production of oral contraceptives (OCs), which, in contrast to condoms, allow women



Obstetrics and gynecology products by life stage

to assert their preference for non-pregnancy.

But as well as producing OCs, ASKA Pharmaceutical is also actively working on developing drugs



Drugs for the treatment of thyroid disease when launched in 1922

to minimize their side effects.

Mr. Yamaguchi again: "We are currently in phase three of developing LF11, which utilizes only progesterone, thus eliminating the side effects associated with estrogen."

Treatment of dysmenorrhea is another core focus. To this end, ASKA has recently launched its DroEthi combination tablets, which, according to Mr. Yamaguchi, provide a "generic alternative to a well-established product already on the market."


While initial feedback has been good, it is only one in a range of products the company offers in this particular field. "One of our strengths," Mr. Yamaguchi explains, "is that we provide a number of products for dysmenorrhea treatment, a field in which we hold around a 50% market share."

And indeed, having long conducted R&D both in-house and with other companies, ASKA is now actively

seeking new collaborations overseas, particularly in the fields of internal medicine, obstetrics and gynecology, and urology.

A two-pronged strategy will see the company introduce unique drugs developed by overseas companies to the Japanese market as well as offering licensing partnerships to overseas companies for drugs it has developed itself.

A Relugolix combination tablet called AKP-022, for instance, is



Total healthcare company with a strong foundation as a specialty pharma company

set to go to clinical trials in July 2023. Focusing on uterine fibroids in females, the product is being positioned as the successor to RELUMINA, and is expected to enable longer durations of administration, and therefore improve patient convenience.

In 2021, meanwhile, the company invested in a partnership with Ha Tay Pharmaceutical Joint Stock Com-

pany in Vietnam, hoping to take advantage of the country's growing economy and medical market. Through this partnership, ASKA is aiming to establish a strong presence in Vietnam and expand into other Asian countries from there.


Looking to the future, ASKA has set itself a number of goals to achieve in the mid-term. "We want to remain the leader in the field of obstetrics and gynecology, both in name and in reality," says the ASKA Pharmaceutical president.

"We contribute to the stable supply of essential drugs and the elimination of unmet needs. For example, in the thyroid disease area, where we already have a market share of more than 90%, we are working on various initiatives. As well as ensuring that thyroid patients have access to a reliable pharmaceutical supply, we are aiming to develop drugs that minimize the side effects of existing drugs, or drugs that

treat thyroid disease with a different approach," Mr. Yamaguchi explains. "Through this we will respond to medical needs that have previously not been met."

Through its provision of drugs and treatments as well as medical equipment and related services, the ultimate aim, Mr. Yamaguchi states, is "to become a total healthcare company and a global company, offering comprehensive health services for females."

ASKA Pharmaceutical Co., Ltd.
www.aska-pharma.co.jp



Three core areas with a focus on pharmaceuticals